SPY продолжает смотреть вниз

Ближайший уровень поддержки по SPY – 193.25 уровень сопротивления – 194.00



CAMP продажа от 20

SRTY смотрим на лонг

URI смотрим на продажу

EMES продажа ниже 95

TCS покупка от 16.50

Gapping up/down: COST +2% and YUM +1% after earnings, COTY +4% after upgrade; SAVE -3% and MON -2% after earnings/guidance, SAP -3% after reports of Job freeze, GPRO -2% after dg Price: null Change: null

Gapping up
In reaction to strong earnings/guidance: COST +2.4%, YUM +1.3%

M&A news: TST +5% (to acquire BoardEx for ~$21 mln), SYMC +3.4% (may consider splitting up security and storage units, according to reports), AGN +1.9% (VRX and Pershing Square intend to increase bid for co), VRX +1.4% (co and Pershing Square intend to increase bid for Allergan (AGN)

Select financial related names showing strength: NBG +2%, ING +1.4%, SAN +1.4%, UBS +1.1%, HSBC +0.9%

Select metals/mining stocks trading higher: HL +3%, GFI +2.2%, AUY +1.6%, ABX +1.4%, IAG +1.3%, SLW +1.3%, GOLD +1.2%, SLV +1%, GDX +0.9%


Other news: GTAT +21.5% (seeing reports that co's first bankruptcy hearing has been scheduled for Thursday), SCOK +11.7% (issues update on construction and financing of underground Syngas Project), WYY +8.6% (receives 4 new federal contract awards; contract has period of performance of one year and total ~$2.7 mln), DRL +6.7% (disclosed the appointment of Nancy Reinhard as acting CFO), TST +5% (to acquire BoardEx for ~$21 mln), CMRX +4.9% (shows potential survival benefit in Adenovirus infection), PAH +3.7% (Pershing square disclosed a 26.1% active stake), TASR +3.7% (body camera momentum builds as adoption of AXON and EVIDENCE.com accelerates), OXGN +3% (announced first patient enrolled in Phase 1b/2 Study of Fosbretabulin combined with Pazopanib in patients with advanced recurrent ovarian cancer), MBLY +2.9% (ahead of TSLA event tomorrow), TKMR +2.5% (cont momentum/Ebola play), JCP +2.3% (ahead of anaylst day), ORAN +1.4% (in talks with other cos to create Netflix (NFLX) like streaming service, according to reports), BCRX +1.1% (present clinical trial results related to investigational drug RAPIVAB at the IDWeek Conference October 8-12)

Analyst comments: COTY +4.2% (upgraded to Neutral from Sell at B. Riley & Co), GLUU +2.3% (upgraded to Buy from Hold at The Benchmark Company), CMI +0.9% (initiated with a Buy at Stifel), LEAF +0.9% (upgraded to Outperform from Neutral at Macquarie)

Gapping down
In reaction to disappointing earnings/guidance: TILE -17.9%, (announces expansion of credit facility, planned bond redemption, share repurchase program ), SAVE -3.2%, (co sees Q3 adjusted operating margin in lower half of previous guidance range) MON -1.6%, RPM -1%, ASX -0.8%,.

Other news: RDY -4% (weak markets in India overnight), SAP -3.5% (reports suggesting job freeze until 2015 ), ICPT -3.2% (co decides not to present FLINT data at AASLD), RIO -2.1% (may still go after a defense deal with Anglo American (AAUKY), according to reports), INFY -1.5% (weak markets in India overnight), ALU -1.1% (still checking), GSK -0.8% (corruption allegations, according to reports out intraday), AZN -0.8% (may be in sympathy with GSK)

Analyst comments: SSNI -2.3% (downgraded to Neutral from Buy at Goldman), GPRO -2.2% (downgraded to Neutral from Overweight at Piper Jaffray), ARP -1.6% (initiated with a Mkt Perform at Raymond James)

Оригинал статьи: gtstocks.com/analytics-08-10-2014.html